<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APS) results from autoantibodies to cell surface <z:chebi fb="1" ids="16247">phospholipids</z:chebi> or <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding proteins resulting in clotting anomalies and can have devastating sequelae, including <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo>, <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, and recurrent <z:hpo ids='HP_0005268'>spontaneous abortions</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, cutaneous manifestations are the first sign of APS in up to 41% of patients </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case report of APS that developed several days after taking <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>/<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical and pathological features of this unique presentation, differential diagnoses, and treatments are discussed </plain></SENT>
</text></document>